DARPA

Baxter, Harvard launch Opsonix

Friday, October 9, 2015

Cambridge, Mass.-based Opsonix has launched with an $8 million Series A financing to develop a pathogen-extracting therapy designed to remove infectious pathogens and toxins from circulating blood.

[Read More]

Inovio receives $24M DARPA grant

Wednesday, September 23, 2015

Inovio Pharmaceuticals has announced that the U.S. Defense Advanced Research Projects Agency (DARPA) has exercised its option to provide an additional $24 million to support the Inovio-led development of multiple treatment and prevention approaches against Ebola. The option exercise, part of the $45 million Ebola program grant announced in April when Inovio received an initial $21 million award, was contingent upon Inovio successfully leading the completion of certain preclinical and clinical development milestones.

[Read More]

Moderna, Merck to develop messenger RNA-based antiviral vaccines

Wednesday, January 14, 2015

Moderna Therapeutics has announced a license and collaboration agreement with Merck, through a subsidiary, for the discovery and development of vaccines and passive immunity treatments against viral diseases using modified messenger RNA (mRNA). Moderna’s work in the collaboration will be led by Valera, its venture focused on the development of mRNA vaccines and therapeutics to fight infectious disease. Moderna is privately held, Cambridge, Mass.-based company founded by Flagship VentureLabs.

[Read More]

Inovio Pharmaceuticals, MedImmune, University of Pennsylvania partner

Wednesday, October 22, 2014

The Defense Advanced Research Projects Agency (DARPA) has awarded $12.2 million for a collaborative study that will be conducted by scientists from the Perelman School of Medicine at the University of PennsylvaniaInovio Pharmaceuticals and MedImmune, the global biologics R&D arm of AstraZeneca. The group will develop DNA-based monoclonal antibodies (mAbs) for infectious disease treatment. DARPA is an agency of the U.S. Department of Defense that creates and supports novel technologies important for national security.

[Read More]

DARPA awards Moderna Therapeutics $25m

Friday, October 4, 2013

Moderna Therapeutics, a company focused on messenger RNA therapeutics, a new treatment modality to enable the in vivo production of therapeutic proteins, has been awarded up to $25 million to research and develop its messenger RNA therapeutics platform as a rapid and reliable way to make antibody-producing drugs to protect against a wide range of known and unknown emerging infectious diseases and engineered biological threats by the Defense Advanced Research Projects Agency (DARPA).

[Read More]